ALSO NOTED: AIDS vaccine researchers years away from success; Amgen reports earnings; and much more...

> Following a series of major setbacks trying to develop a vaccine for AIDS, pessimistic researchers say they're years away from success. Report

> AstraZeneca and Amgen have posted their earnings. Earnings report

> FDA inspectors found 49 problems at Merck's West Point, PA, vaccine plant--problems independent experts called "serious concerns." Merck report

> Sanofi-Aventis announced that small amounts of an impurity have been found in batches of its heparin injection Lovenox. Sanofi report

> You can't say Takeda Pharmaceutical is unwilling to take risks. The Japanese drugmaker went out on an $8.8 billion limb in bidding for the U.S. biotech Millennium Pharmaceuticals. Investors weren't impressed; they dragged share prices down by 8 percent almost immediately. Report

> After more than a decade of attempts, it looks like Congress might finally pass a bill that would block health insurers from denying coverage to otherwise healthy persons based on their genetic predisposition to come down with a particular disease. Report

> GSK is confident it can prevail in vaccine battle. Report

> Genocea Biosciences has been recognized as the best vaccine startup company at a meeting of the World Vaccine Congress in Washington D.C. Report

And Finally... The Democratic Party may not have its nominee yet, but Big Pharma apparently does. At a mock election this week at the DTC National Conference, Barack Obama trounced Hillary Clinton with 59 percent of the vote to her 40 percent. Election report

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.